As Sunovion Pharmaceuticals Inc., Sepracor will retain its corporate headquarters in Marlborough, Massachusetts. The company will maintain its commercial function for all brands including LUNESTA?®, XOPENEX?®, XOPENEX HFA?®, BROVANA?®, OMNARIS?® and ALVESCO?® in Massachusetts while its strong R&D operations will be located in both Fort Lee, New Jersey and Massachusetts.

"The past year has been one of tremendous change and growth for Sepracor as we have become a key part of the DSP organization," said Mark Iwicki, President and Chief Operating Officer of Sepracor Inc. "Building on the merger with DSPA, we have the exciting opportunity to deliver increased R&D capabilities that come from combining our two organizations, leverage our commercial excellence, and expand our global presence. We look forward to achieving these goals as we anticipate the formal name change to Sunovion Pharmaceuticals Inc. later this year."

SOURCE Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd.